In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: Implications for treatment of HIV infection and other immune disorders

Priscilla Biswas, Barbara Mantelli, Hamid Hasson, Andrea Vecchi, Abby Saniabadi, Adriano Lazzarin, Alberto Beretta

Research output: Contribution to journalArticlepeer-review

Abstract

Therapeutic purging of myeloid cells (monocytes and granulocytes) (MYP) has been proposed as a treatment of severe inflammatory conditions like ulcerative colitis and rheumatoid arthritis. Although direct purging of inflammatory cells contributes to its efficacy, the precise mechanism of action is still unclear. We have tested MYP in a pilot study on 12 patients with chronic HIV infection, of whom 6 underwent MYP. Three/6 MYP patients and none of the controls displayed a strong and long-lasting decrease of cells expressing CXCR3, a major chemokine receptor responsible for trafficking of inflammatory cells. In these three patients, the number of circulating CD4 T cells increased during treatment. The data provide a rational for the use of MYP as a therapeutic tool acting via the modulation of immune cell trafficking.

Original languageEnglish
Pages (from-to)355-358
Number of pages4
JournalClinical Immunology
Volume109
Issue number3
DOIs
Publication statusPublished - Dec 2003

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: Implications for treatment of HIV infection and other immune disorders'. Together they form a unique fingerprint.

Cite this